Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

Abstract Introduction Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late‐onset AD (LOAD) and autosomal‐dominant AD (ADAD). Few studies have evaluated...

Full description

Bibliographic Details
Main Authors: Rachel L. Henson, Eric Doran, Bradley T. Christian, Benjamin L. Handen, William E. Klunk, Florence Lai, Joseph H. Lee, H. Diana Rosas, Nicole Schupf, Shahid H. Zaman, Ira T. Lott, Anne M. Fagan
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
biomarkers
cerebrospinal fluid
Down syndrome
amyloid
tau
Online Access:https://doi.org/10.1002/dad2.12057

Internet

https://doi.org/10.1002/dad2.12057

Similar Items